Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress

Cogent Biosciences (Nasdaq: COGT) will present new data at the European Hematology Association (EHA) 2026 Congress in Stockholm, June 11-14, 2026.

Rhea-AI Summary

Cogent Biosciences (Nasdaq: COGT) will present new data at the European Hematology Association (EHA) 2026 Congress in Stockholm, June 11-14, 2026.

Highlights include a pivotal APEX trial oral presentation in Advanced Systemic Mastocytosis, an AdvSM poster, and a preclinical JAK2 V617F poster on CGT1145.

Argus May 12 session

+1.26% close to close Open Argus

Details

News Market Reaction – COGT

On May 12, the day this news came out, COGT closed 1.26% above the previous close.

Data tracked by StockTitan Argus for the May 12 session.

Key Figures

EHA 2026 dates: June 11–14, 2026 Bezuclastinib oral date: June 13, 2026 Oral session time: 17:15–18:30 CEST +5 more

EHA 2026 dates

June 11–14, 2026

European Hematology Association Congress schedule

Bezuclastinib oral date

June 13, 2026

APEX pivotal data oral presentation session date

Oral session time

17:15–18:30 CEST

Bezuclastinib APEX oral presentation window

Poster session date

June 12, 2026

AdvSM and JAK2 V617F poster presentations

Poster session time

18:45–19:45 CEST

AdvSM and JAK2 V617F poster presentation window

Oral session code

S438

Myeloproliferative Neoplasms – Clinical oral session identifier

AdvSM poster number

PF885

Bezuclastinib AdvSM APEX trial poster identifier

JAK2 poster number

PF853

CGT1145 JAK2 V617F preclinical poster identifier

Historical Context

5 past events · Latest: May 05

5 events

1. May 05

   Earnings and update

   24h Move

   +0.7%

   Q1 2026 results, NDAs under review, and cash runway into 2028.

2. Apr 21

   Clinical data update

   24h Move

   -0.7%

   Positive Phase 3 PEAK GIST data selected for ASCO oral presentation.

3. Apr 17

   Preclinical pipeline data

   24h Move

   +2.9%

   AACR preclinical results for CGT1263 and CGT4255 showing strong selectivity and activity.

4. Apr 01

   NDA submission

   24h Move

   -8.4%

   NDA submission for bezuclastinib in imatinib‑resistant GIST with favorable Phase 3 outcomes.

5. Mar 16

   Regulatory milestone

   24h Move

   +5.0%

   FDA acceptance of bezuclastinib NDA in NonAdvSM with a set PDUFA date.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

advanced systemic mastocytosis, jak2 v617f, myeloproliferative neoplasms, mutant-selective inhibitor

4 terms

advanced systemic mastocytosis medical

"Pivotal data from APEX trial in Advanced Systemic Mastocytosis accepted for oral..."

Advanced systemic mastocytosis is a rare, aggressive disease in which certain immune cells called mast cells grow uncontrollably and build up in organs such as the bone marrow, liver, spleen or skin, causing organ damage and severe symptoms. For investors, it matters because the condition represents a high unmet medical need with clear clinical endpoints, potentially sizable but specialized treatment markets, and distinct regulatory and trial pathways that can make successful therapies commercially and strategically important for biotech and pharmaceutical companies.

jak2 v617f medical

"Preclinical data from selective, potent JAK2 V617F program accepted for poster..."

A single, well-known change in the JAK2 gene that acts like a stuck “on” switch in blood-cell growth control, causing certain chronic blood disorders and some blood cancers. It matters to investors because detecting this mutation guides diagnosis, patient selection for targeted drugs, and demand for companion diagnostics and therapies; advances or setbacks in tests or treatments tied to the mutation can affect the commercial value of related medical companies.

myeloproliferative neoplasms medical

"Oral Session: S438 Myeloproliferative Neoplasms – Clinical"

Myeloproliferative neoplasms are a group of blood cancers caused by the bone marrow producing too many of one or more types of blood cells, which can crowd out normal cells and impair blood flow. Investors pay attention because these conditions create clear medical needs and predictable markets for diagnostics, therapies and follow-up care—similar to a failing factory that creates demand for repair services and replacement parts—affecting drug development, regulatory milestones and potential sales.

mutant-selective inhibitor medical

"CGT1145 a novel, wild-type-sparing, JAK2 V617F mutant-selective inhibitor"

A mutant-selective inhibitor is a drug designed to block the activity of a specific abnormal (mutated) protein that drives disease while leaving the normal version of that protein largely unaffected. Think of it like a key that only fits a warped lock: it aims to stop the harmful process with fewer side effects on healthy cells. For investors, this can mean a clearer path to regulatory approval, stronger clinical results, and potential premium pricing, but often for a narrower group of patients.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Pivotal data from APEX trial in Advanced Systemic Mastocytosis accepted for oral presentation; Cogent’s third oral presentation of pivotal data with bezuclastinib at major medical meetings
   
• Preclinical data from selective, potent JAK2 V617F program accepted for poster presentation

WALTHAM, Mass. and BOULDER, Colo., May 12, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced two presentations from the company’s Advanced Systemic Mastocytosis (AdvSM) program, including an oral presentation highlighting the results of the APEX trial, as well as a poster presentation from its emerging JAK2 V617F program at the European Hematology Association (EHA) Congress being held in Stockholm, Sweden, June 11-14, 2026.

Details of the presentations are as follows:

Bezuclastinib 

Oral Presentation

Abstract Title: Efficacy and Safety of Bezuclastinib in Patients With Advanced Systemic Mastocytosis: Primary Results From the Apex Study
Presenter: Daniel DeAngelo, M.D., Ph.D., Chief of the Division of Leukemia at the Dana-Farber Cancer Institute and Professor of Medicine, Harvard Medical School
Session Date and Time: June 13, 2026 – 17:15 – 18:30 CEST (11:15 AM ET – 12:30 PM ET)
Oral Session: S438 Myeloproliferative Neoplasms – Clinical
Session Room: A2-3 Hall

Poster Presentation

Abstract Title: The Effect of Bezuclastinib on the Pathobiology of Advanced Systemic Mastocytosis: Results from the Pivotal Apex Trial
Poster #: PF885
Presenter: Tracy George, M.D., President and Chief Scientific Officer at ARUP Laboratories, Professor of Pathology at the University of Utah School of Medicine  
Session Date and Time: June 12, 2026 – 18:45-19:45 CEST (12:45pm - 1:45pm ET)

JAK2 V617F

Poster Presentation

Abstract Title: Preclinical characterization of CGT1145 a novel, wild-type-sparing, JAK2 V617F mutant-selective inhibitor
Poster #: PF853
Presenter: Mark J Chicarelli, Senior Director Medicinal Chemistry, Cogent Biosciences
Session Date and Time: June 12, 2026 – 18:45-19:45 CEST (12:45pm - 1:45pm ET)

About Cogent Biosciences, Inc.
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. In addition, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in ErbB2, PI3Kα, KRAS and JAK2. Cogent Biosciences is based in Waltham, MA and Boulder, CO. Visit our website for more information at www.cogentbio.com. Follow Cogent Biosciences on social media: X (formerly known as Twitter) and LinkedIn. Information that may be important to investors will be routinely posted on our website and X.

Contact:
Christi Waarich
Senior Director, Investor Relations
christi.waarich@cogentbio.com
617-830-1653

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What will Cogent Biosciences (COGT) present at EHA 2026?

Cogent Biosciences will present pivotal APEX trial data in Advanced Systemic Mastocytosis and preclinical JAK2 V617F data. According to Cogent Biosciences, these include one oral presentation and two posters at the EHA 2026 Congress in Stockholm.

When is Cogent Biosciences' bezuclastinib APEX oral presentation at EHA 2026?

The bezuclastinib APEX oral presentation is scheduled for June 13, 2026, from 17:15 to 18:30 CEST. According to Cogent Biosciences, it is part of oral session S438 on myeloproliferative neoplasms in room A2-3 Hall.

What is the focus of Cogent Biosciences' APEX trial data in Advanced Systemic Mastocytosis?

The APEX trial presentation focuses on the efficacy and safety of bezuclastinib in Advanced Systemic Mastocytosis. According to Cogent Biosciences, it will share primary results from this pivotal study in an oral session at EHA 2026.

Which posters will Cogent Biosciences (COGT) present at EHA 2026?

Cogent Biosciences will present two posters: one on bezuclastinib’s effect on Advanced Systemic Mastocytosis pathobiology and one on CGT1145, a JAK2 V617F-selective inhibitor. According to Cogent Biosciences, both posters are scheduled for June 12, 2026.

Who are the presenters for Cogent Biosciences' key EHA 2026 sessions?

Daniel DeAngelo will present the APEX oral data, while Tracy George will present the AdvSM pathobiology poster. According to Cogent Biosciences, Mark J Chicarelli will present the preclinical JAK2 V617F CGT1145 poster.